Todd Bazemore Sells 4,653 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) insider Todd Bazemore sold 4,653 shares of the firm’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total transaction of $22,101.75. Following the sale, the insider now owns 83,040 shares in the company, valued at $394,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Todd Bazemore also recently made the following trade(s):

• On Friday, May 31st, Todd Bazemore sold 2,093 shares of KALA BIO stock. The stock was sold at an average price of $6.09, for a total transaction of $12,746.37.

KALA BIO Stock Up 9.9 %

Shares of KALA stock opened at $7.09 on Friday. The company has a current ratio of 4.22, a quick ratio of 4.22 and a debt-to-equity ratio of 4.92. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $16.11. The firm’s fifty day moving average price is $6.39 and its two-hundred day moving average price is $7.02. The firm has a market capitalization of $19.99 million, a P/E ratio of -0.47 and a beta of -1.97.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($4.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.89) by ($1.31). On average, equities analysts predict that KALA BIO, Inc. will post -14.49 EPS for the current fiscal year.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned about 0.16% of KALA BIO at the end of the most recent quarter. Institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

KALA has been the topic of a number of research analyst reports. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a report on Monday, April 1st. HC Wainwright dropped their price objective on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, May 17th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.